Jiangxi Xinglin Baima Pharmaceutical Co. Ltd.

Primary Study Objective: To evaluate the pharmacokinetic characteristics and bioequivalence of a single oral dose of sitagliptin metformin tablets (II) [specification: each tablet contains 50 mg of sitagliptin phosphate (calculated as sitagliptin) and 850 mg of metformin hydrochloride, applicant: Jiangxi Xinglin Baima Pharmaceutical Co., Ltd.] and a reference formulation [trade name: JANUMET®, specification: each tablet contains 50 mg of sitagliptin phosphate (calculated as sitagliptin) and 850 mg of metformin hydrochloride, licensee: MSD Merck Sharp & Dohme AG] in healthy Chinese adult subjects under fasting and fed conditions. Secondary study objectives: To investigate the safety of the test formulation of sitagliptin metformin tablets (II) [specification: each tablet contains 50 mg of sitagliptin phosphate (calculated as sitagliptin) and 850 mg of metformin hydrochloride] and the reference formulation [trade name: JANUMET®, specification: each tablet contains 50 mg of sitagliptin phosphate (calculated as sitagliptin) and 850 mg of metformin hydrochloride] in healthy adult Chinese subjects.

A single-center, randomized, open-label, two-dose, four-period, two-sequence, crossover bioequivalence study of telmisartan capsules 40 mg after a single oral dose in healthy Chinese volunteers

Main study objectives To evaluate the pharmacokinetic characteristics of the test preparation Telmisartan Capsules (40 mg) provided by Jiangxi Xinglin Baima Pharmaceutical Co., Ltd. and the reference preparation Telmisartan Tablets (trade name: Micardis®, 40 mg) certified by Boehringer Ingelheim International GmbH in Chinese healthy subjects under fasting and postprandial conditions, compare their relative bioavailability, evaluate the bioequivalence between the two preparations, and provide a basis for the consistency evaluation of the test preparation. Secondary study objectives To study the safety of a single oral administration of 40 mg of the test preparation Telmisartan Capsules or the reference preparation Telmisartan Tablets (trade name: Micardis®, 40 mg) in healthy subjects.